Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of modified SMILE chemotherapy for advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma
jRCTs061260056Phase 2Recruiting
- Sponsor
- Servier
- Start
- Sep 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methotrexate, ifosfamide, pegaspargase, etoposide and dexamethasone in extranodal natural killer/T-cell lymphoma (ENKTL), sponsored by Servier. Primary endpoint: Overall response rate. Started Sep 2026; status: recruiting.
02
Drugs
methotrexateifosfamidepegaspargaseetoposidedexamethasone
03
Conditions
extranodal natural killer/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on jRCTs061260056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061260056.